NCT07509749 (GVHD) is a Phase 2 clinical trial of Ruxolitinib and Methylprednisolone in GVHD, Acute, sponsored by Daihong Liu.

Who is sponsoring NCT07509749?

NCT07509749 is sponsored by Daihong Liu.

What drugs are being tested in NCT07509749?

Interventions in NCT07509749: Ruxolitinib and Methylprednisolone, Methylprednisolone.

What condition does NCT07509749 study?

NCT07509749 studies GVHD, Acute, Stem Cell Transplant Complications.

Is NCT07509749 still recruiting?

NCT07509749 is currently recruiting now. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT07509749: GVHD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

Recruiting now Phase 2 Last updated 3 April 2026

What this trial tests

Phase 2 trial testing Ruxolitinib and Methylprednisolone in GVHD, Acute in 54 participants. Currently enrolling.

Timeline

30 June 2025

Primary endpoint
30 December 2027

30 December 2027

Quick facts

Lead sponsor	Daihong Liu
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	30 June 2025
Primary completion	30 December 2027
Estimated completion	30 December 2027
Sites	1 location across China

Drugs / interventions tested

Ruxolitinib and Methylprednisolone
Methylprednisolone (methylprednisolone) — full drug profile →

Conditions studied

GVHD, Acute — all drugs for GVHD, Acute →
Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →

Sponsor

Daihong Liu — full company profile →

Who can join

14 and older, any sex, with GVHD, Acute or Stem Cell Transplant Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the severe acute GVHD (graft-versus-host disease )

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for GVHD, Acute

Currently open trials in the same condition.

NCT04118556 — Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT · Phase 2 · recruiting

Other Daihong Liu trials

Trials by the same sponsor.

NCT07489534 — Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction · Phase 2 · recruiting
NCT07321301 — Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia · Phase 2 · recruiting
NCT07368634 — Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation · Phase 1, PHASE2 · recruiting
NCT07450391 — EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders · Phase 1, PHASE2 · recruiting
NCT07340723 — Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07509749 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daihong Liu
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07509749.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing